Authors' reply

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2705-2706

  Baddley, John W ^a   Ostrosky Zeichner, Luis ^b   Bhavnani, Sujata M ^c   Andes, David R ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

AGE; ANTIFUNGAL SUSCEPTIBILITY; CANDIDEMIA; DISEASE SEVERITY; HOST SUSCEPTIBILITY; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 67049164686     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01411-08     Document Type: Letter

References (10)

1. Andes, D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. N. Am. 20:679-697.
2. Andes, D., and M. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
3. Baddley, J. W. M. Patel, S. Bhavnani, S. A. Moser, and D. R. Andes. 2008. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 52:3022-3028.
4. Clancy, C. J., V. L. Yu, A. J. Morris, D. R. Snyderman, and M. H. Nguyen. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177.
5. Lee, S. C., C. P. Fung, J. S. Huang, C. J. Tsai, K. S. Chen, H. Y. Chen, N. Lee, L. C. See, and W. B. Shieh. 2000. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob. Agents Chemother. 44:2715-2718.
6. Louie, A., G. L. Drusano, P. Banerjee, Q. F. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
7. Ostrosky-Zeichner, L., J. H. Rex. M. A. Pfaller, D. J. Diekema, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. D. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob. Agents Chemother. 52:4175-4177.
8. Pai, M. P., R. S. Turpin, and K. W. Garey. 2007. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 51:35-39.
9. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancasster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin. Infect. Dis. 24:235-247.
10. Rodriguez-Tudela, J. L., B. Almirante, D. Rodriguez-Pardo, F. Laguna, J. P. Donnelly, J. W. Mouton, A. Pahissa, and M. Cuenca-Estrella. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604.